Ipsen has entered an exclusive global collaboration with Skyhawk Therapeutics for the discovery and development of new RNA-modulating small molecules for treating rare neurological disorders. Ipsen will have the option to acquire sole global licensing rights for developing two successful development candidates (DC).
Upon successful DC nomination, Ipsen will assume all subsequent development and commercialisation activities.
The company plans to draw on its existing neuroscience expertise — particularly in movement disorders — to advance these potential therapies.
Skyhawk has technology which is able to rapidly generate RNA-targeting small molecules for several therapeutic areas, including rare neurological conditions. This will allow the duo to investigate RNA targets which were previously dismissed, allowing the broadening of potential disease targets.
Under the deal, Skyhawk is eligible to receive up to $1.8bn in payments tied to meeting development, regulatory and commercial milestones. Additionally, the deal involves an upfront payment for the option and research partnership, as well as tiered royalty payments in the future.
